Quality of life in patients with wet age-related macular degeneration treated with photodynamic therapy;Apport de la photothérapie dynamique dans la qualité de vie des patients atteints de dégénérescence maculaire exsudative

Journal Francais d'Ophtalmologie

Volumn 30, Issue 3, 2007, Pages 233-238

  Laouar, K ^a,b   Dupeyron, G ^b,c   Audemard, D ^b,c   Arnaud, B ^a   Arndt, C ^a  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b NÎMES UNIVERSITY HOSPITAL   (France)

^c Institut ARAMAV   (France)

Author keywords

ARMD; Low vision; Photodynamic therapy; Quality of life; Rehabilitation

Indexed keywords

EID: 34147165943     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0181-5512(07)89583-0     Document Type: Article

References (20)

1. Coscas G. Dégénérescence maculaire liée à l'âge et néovaisseaux sous-rétiniens: première cause de cécité acquise chez l'adulte en France. Rev Prat, 1991;41:2320-2
2. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol, 1999;117:1329-45
3. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol, 2001;131:541-60.
4. Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, et al. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol, 2002;120:1443-54.
5. Wolffsohn JS, Cochrane AL. Design of the low vision quality-of-life questionnaire (LVQOL) and measuring the outcome of low-vision rehabilitation. Am J Ophthalmol, 2000;130:793-802.
6. Sharma S, Hollands H, Brown GC, Brown MM, Shah GK, Sharma SM. Improvement in quality of life from photodynamic therapy: a Canadian perspective. Can J Ophthalmol, 2001;36:332-8.
7. Stelmack JA, Stelmack TR, Massof RW. Measuring low-vision rehabilitation outcomes with the NEI VFQ-25. Invest Ophthalmol Vis Sci, 2002;43:2859-68.
8. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology, 2001;108:2051-9.
9. Scott IU, Smiddy WE, Schiffman J, Feuer WJ, Pappas CJ. Quality of life of low-vision patients and the impact of low-vision services. Am J Ophthalmol, 1999;128:54-62.
10. Nilsson UL, Nilsson SE. Rehabilitation of the visually handicapped with advanced macular degeneration. A follow-up study at the Low Vision Clinic, Department of Ophthalmology, University of Linkoping. Doc Ophthalmol, 1986;62:345-67.
11. Nilsson UL, Frennesson C, Nilsson SE. Patients with AMD and a large absolute central scotoma can be trained successfully to use eccentric viewing, as demonstrated in a scanning laser ophthalmoscope. Vision Res, 2003;43:1777-87.
12. Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol, 1998;116:514-20.
13. Stein JD, Brown MM, Brown GC, Hollands H, Sharma S. Quality of life with macular degeneration: perceptions of patients, clinicians, and community members. Br J Ophthalmol, 2003;87:8-12.
14. Gresset J, Boisjoly H, Nguyen TQ, Boutin J, Charest M. Validation of French-language versions of the Visual Functioning Index (VF-14) and the Cataract Symptom Score. Can J Ophthalmol, 1997;32:31-7.
15. Riusala A, Sarna S, Immonen I. Visual function index (VF-14) in exudative age-related macular degeneration of long duration. Am J Ophthalmol, 2003;135:206-12.
16. Baudouin C, Bechetoille A, Bron A, Denis P, Nordmann JP, Renard JP, Rouland JF, Sellem E, Rigeade MC, Arnould B. Intérêt de la mesure de la qualité de vie (QDV) et de l'observance thérapeutique chez les patients atteints de glaucome chronique à angle ouvert. Groupe d'étude Glaucome et Qualité de Vie. J Fr Ophtalmol, 2000;23:1057-64.
17. Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol, 1998;116:1496-504.
18. Clemons TE, Chew EY, Bressler SB, McBee W; Age-Related Eye Disease Study Research Group. National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS Report No. 10. Arch Ophthalmol, 2003;121:211-7.
19. Miskala PH, Bass EB, Bressler NM, Childs AL, Hawkins BS, Mangione CM, et al. Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no. 12. Ophthalmology, 2004;111:1981-92.
20. Ergun E, Maar N, Radner W, Barbazetto I, Schmidt-Erfurth U, Stur M. Scotoma size and reading speed in patients with subfoveal occult choroidal neovascularization in age-related macular degeneration. Ophthalmology, 2003;110:65-9.